title: Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation.
abstract: We evaluated the efficacy of the prophylactic administration of epsilon-aminocaproic acid and tranexamic acid for reducing blood product requirements in orthotopic liver transplantation (OLT) in a prospective, double-blinded study performed in 132 consecutive patients. Patients were randomized to three groups and given one of three drugs prophylactically: tranexamic acid, 10 mg. kg(-1). h(-1); epsilon-aminocaproic acid, 16 mg. kg(-1). h(-1), and placebo (isotonic saline). Perioperative management was standardized. Coagulation tests, thromboelastogram, and blood requirements were recorded during OLT and in the first 24 h. There were no differences in diagnosis, Child score, or preoperative coagulation tests among groups. Administration of packed red blood cells was significantly reduced (P = 0.023) during OLT in the tranexamic acid group, but not in the epsilon-aminocaproic acid group. There were no differences in transfusion requirements after OLT. Thromboembolic events, reoperations, and mortality were similar in the three groups. Prophylactic administration of tranexamic acid, but not epsilon-aminocaproic acid, significantly reduces total packed red blood cell usage during OLT.
  
  
  CONCLUSIONS
  In a randomized study of 132 consecutive patients undergoing liver transplantation, we found that tranexamic acid, but not epsilon-aminocaproic acid, reduced intraoperative total packed red blood cell transfusion.
authors.affiliation: Department of Anaesthesiology and Surgery, Princeps D'Espanya Hospital, Barcelona, Spain. antonia@servinter.com
authors.forename: A
authors.initials: A
authors.lastname: Dalmau
authors.forename: A
authors.initials: A
authors.lastname: Sabaté
authors.forename: F
authors.initials: F
authors.lastname: Acosta
authors.forename: L
authors.initials: L
authors.lastname: Garcia-Huete
authors.forename: M
authors.initials: M
authors.lastname: Koo
authors.forename: T
authors.initials: T
authors.lastname: Sansano
authors.forename: A
authors.initials: A
authors.lastname: Rafecas
authors.forename: J
authors.initials: J
authors.lastname: Figueras
authors.forename: E
authors.initials: E
authors.lastname: Jaurrieta
authors.forename: P
authors.initials: P
authors.lastname: Parrilla
mesh_terms: D000328:Adult; D000368:Aged; D015119:Aminocaproic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D000933:Antifibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects; D016913:Blood Component Transfusion; D016063:Blood Loss, Surgical / Q000517:prevention & control; D004311:Double-Blind Method; D017707:Erythrocyte Transfusion; D005260:Female; D006801:Humans; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014148:Tranexamic Acid / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000933:Antifibrinolytic Agents; D014148:Tranexamic Acid; D015119:Aminocaproic Acid